Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: A randomized controlled trial

Julien Freitag, Dan Bates, James Wickham, Kiran Shah, Leesa Huguenin, Abi Tenen, Kade Paterson, Richard Boyd

Research output: Contribution to journalArticle

8 Citations (Scopus)
35 Downloads (Pure)


AIM:To evaluate the efficacy of autologous adipose-derived mesenchymal stem cell (ADMSC) therapy on pain, function and disease modification in knee osteoarthritis.METHODS:30 participants with symptomatic knee osteoarthritis were randomized into three groups. Two treatment groups received intra-articular ADMSC therapy consisting of either a single injection (100 × 106 ADMSCs) or two injections (100 × 106 ADMSCs at baseline and 6 months). The third group served as control and continued conservative management.RESULTS:No serious adverse events were observed. Both treatment groups receiving ADMSCs showed clinically significant pain and functional improvement at completion of follow-up at 12 months. Radiological analysis using the Magnetic Resonance Imaging Osteoarthritis Knee Score indicated modification of disease progression. CONCLUSION: Autologous ADMSC therapy appears to be a safe and effective therapy for knee osteoarthritis and may have the potential to prevent disease progression.
Original languageEnglish
Pages (from-to)213-230
Number of pages18
JournalRegenerative Medicine
Issue number3
Early online date14 Feb 2019
Publication statusPublished - 2019


Cite this